Mahmoudzadeh Pouya, Tousi Adib, Ramezani Alireza, Soheilian Roham, Soheilian Masoud
Ophthalmology Department and Ophthalmic Research Center, Labbafinejad Medical Center, School of Medicine, Shahid Beheshti University of Medical Sciences, Pasdaran Ave. Boostan 9 St, 16666, Tehran, Iran.
Int Ophthalmol. 2015 Jun;35(3):395-402. doi: 10.1007/s10792-014-9960-6. Epub 2014 Jun 12.
The aim of the study was to assess the clinical features and treatment responses in Iranian patients with sarcoid uveitis. A retrospective review of patients diagnosed with sarcoid uveitis from 1996 to 2010 was performed in a referral clinic in Tehran, Iran. Demographic and clinical features of patients, treatment modalities and therapeutic responses, and outcomes were recorded. Sixty-six eyes from 36 patients were studied. Twenty cases had biopsy-proven sarcoidosis. Mean duration of follow-up was 44.7 ± 45 months (range 3-175). Thirty-six eyes (54.5 %) had intermediate uveitis, 25 (37.9 %) panuveitis, and 5 (7.6 %) anterior uveitis. Twenty patients (55.5 %) responded to both systemic and/or topical corticosteroids, and 16 (44.4 %) required immunomodulatory drugs for control of uveitis. All of the patients finally responded to treatment in the form of inflammation reduction and/or vision improvement. The average time interval before initial clinical response following treatment was 3.2 ± 3 months (range 1-72). This study disclosed a higher predominance of females and intermediate form of uveitis in Iranian patients with sarcoid uveitis. Use of immunomodulatory drugs combined with corticosteroids resulted in good visual outcome and control of uveitis with a possible fewer corticosteroid side effects.
该研究的目的是评估伊朗结节病性葡萄膜炎患者的临床特征及治疗反应。对1996年至2010年在伊朗德黑兰一家转诊诊所诊断为结节病性葡萄膜炎的患者进行了回顾性研究。记录了患者的人口统计学和临床特征、治疗方式及治疗反应以及结局。对36例患者的66只眼睛进行了研究。20例经活检证实为结节病。平均随访时间为44.7±45个月（范围3 - 175个月）。36只眼睛（54.5%）为中间葡萄膜炎，25只（37.9%）为全葡萄膜炎，5只（7.6%）为前葡萄膜炎。20例患者（55.5%）对全身和/或局部皮质类固醇有反应，16例（44.4%）需要免疫调节药物来控制葡萄膜炎。所有患者最终均以炎症减轻和/或视力改善的形式对治疗有反应。治疗后至首次临床反应的平均时间间隔为3.2±3个月（范围1 - 72个月）。这项研究揭示，伊朗结节病性葡萄膜炎患者中女性占比更高，且中间型葡萄膜炎更为多见。使用免疫调节药物联合皮质类固醇可带来良好的视力结局，并控制葡萄膜炎，同时可能减少皮质类固醇的副作用。
